Canada: Prohibition Order Granted Against Generic VIREAD Product

Last Updated: October 24 2016
Article by Lilly Sormaz

On August 23, 2016, the Federal Court released the public judgment and reasons by Justice Brown in 2016 FC 857.  The case was a prohibition proceeding pursuant to s. 6 of the NOC Regulations relating to Canadian Patent No. 2,261,619, which expires on July 25, 2017.  The 619 Patent claims tenofovir disoproxil fumarate – a prodrug present in Gilead's VIREAD used in the treatment and prophylaxis of HIV. The prodrug increases the oral bioavailability of the parent drug, tenofovir. A separate companion decision of Justice Brown relating to Canadian Patent No. 2,512,475, listed against Gilead's TRUVADA (tenofovir disoproxil fumarate  + emtricitabine) product, is reported here.

The only asserted claim of the 619 Patent was claim 32, directed to tenofovir disoproxil and its salts, tautomers and solvates. Justice Brown concluded that Apotex's allegations of anticipation, obviousness, invalid selection patent, and lack of utility were not justified and issued the prohibition order sought by Gilead. Justice Brown also held that a previous decision on the 619 Patent involving a different generic was not binding on conclusions of invalidity.

Blinding of Experts

The parties chose different methods to gather information from their expert witnesses. Counsel for Gilead provided the legal framework to its experts early, including legal tests for anticipation, obviousness, and utility. Counsel for Apotex did so after the experts had drawn their own conclusions on issues such as the promise of the patent, claim construction, and the prior art, thereby "blinding" its experts.

Justice Brown concluded that the blinding of a witness is one of perhaps several factors that goes to the weight of evidence, but it is not a matter that goes to admissibility. He held that the blinding issue is a question of relevance, reliability and weight, and is not a doctrinal matter. Generally, Justice Brown preferred the expert testimony of Gilead's expert witnesses in part because of the greater experience and knowledge of Gilead's expert witnessnes compared to Apotex's expert witnesses. One of Apotex's witnesses also admitted that his affidavit contained two significant false statements regarding the state of the art.


Justice Brown concluded that claim 32 of the 619 Patent was not anticipated by EP 0 481 214 because the latter did not disclose tenofovir disoproxil or even that a prodrug moiety could contain a carbonate group. Justice Brown deemed it significant that Gilead's expert witness explained that the skilled person would not have understood that EP 214 included carbonates, because of the conspicuous absence of carbonates from any explicit disclosure, including the complete absence of carbonates from the explanations and examples provided in EP 214.


Justice Brown concluded that tenofovir disoproxil was not obvious or obvious to try. Justice Brown, reading the 619 Patent through the eyes of the unimaginative skilled person, was unable to find that the carbonate subgroup was uninventive and either self-evident or "obvious to try". The prodrug literature on phosphonate nucleotides for antivirals suggested that carbonates would be unstable. Justice Brown further held that Gilead's research team at that time was acting with an inventive spark and expected a period of trial and error before achieving their goal.

Selection Patent

Justice Brown did not accept Apotex's allegation that claim 32 of the 619 Patent was an invalid selection from the genus disclosed in EP 214. He held that even if EP 214 included tenofovir disoproxil (which he found that it did not) Gilead's prodrug presented special advantages for efficient oral delivery that were not previously disclosed. He noted Examples 15 and 16 of the 619 Patent regarding the specific oral bioavailability of tenofovir disoproxil.


Justice Brown concluded that the promise of the 619 Patent is efficient oral delivery of the parent compound (e.g. tenofovir) through its prodrug, which has a specific carbonate moiety, yielding tenofovir disoproxil. To establish utility, he stated that he is not bound only by the contents of the 619 Patent. He considered the tests disclosed in the 619 Patent and prior art disclosures, which showed improved bioavailability of tenofovir disoproxil over tenofovir.

Justice Brown granted Gilead's prohibition application and awarded costs to Gilead.

A copy of Justice Brown's decision may be found here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions